Metabolic and Renal Outcomes of Empagliflozin among Emirati Patients with Type 2 Diabetes
Abstract
Background: In the last few decades, diabetes mellitus has become one the most prevalent disease and the 7th leading cause of death worldwide. Many studies shows that empagliflozin improves glycemic control in type 2 diabetic (T2DM) patients and added to several clinical treatment pathways, however, metabolic and kidney outcomes studies have not been stablished on United Arab Emirates (UAE) national patients. Objective: To examine the metabolic outcome of empagliflozin when added as an antidiabetic drug for Type 2 diabetic patients and the short-term effect on renal outcomes. Methods: A retrospective chart review, recruiting 188 patients in 2 groups of uncontrolled T2DM patients with glycosylated hemoglobin (HbA1c) ≥ 7.5%. A group receiving either empagliflozin 10 or 25mg tablet as a newly added glucose-lowering agent and a group receiving standard of care (SOC). For both groups, other diabetic medication remains unchanged for at least the first 3 months, with a median follow-up time of 1-year in Oud Al Touba Diagnostic Center in Al Ain, UAE. Results: The effect of empagliflozin 10mg on HbA1c reduction was insignificant compared to SOC with mean HbA1c reduction of 0.3 and 0.4 compared to baseline data at week 12 and 48 respectively, however, patients who started or shifted to empagliflozin 25mg had a significant difference in the mean change from the baseline to study exit compared to SOC of 0.5%, 95% CI 0.36 ‒ 0.78, P < 0.05), with mean HbA1c reduction of 0.5 and 0.6 at…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.